BFEC
HRMY icon

Benjamin F. Edwards & Company’s Harmony Biosciences HRMY Stock Holding History

Benjamin F. Edwards & Company’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-92
Closed -$3K – 2167
2023
Q4 		$3K Buy
+92
New +$2.57K ﹤0.01% 1948

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $86.2B AUM 12.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Benjamin F. Edwards & Company's HRMY Position: Q1 2024 in Review

Benjamin F. Edwards & Company sold out of Harmony Biosciences (HRMY) in Q1 2024, closing a stake of 92 shares — an estimated $3K sold.

Benjamin F. Edwards & Company first reported a position in HRMY in Q4 2023 and held it in 1 quarter. The position peaked at $3K in Q4 2023. 208 funds tracked by Wall St. Rank hold HRMY as of Q1 2024.

  • Benjamin F. Edwards & Company reported no remaining Harmony Biosciences position as of Q1 2024 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 92 Harmony Biosciences shares in Q1 2024, an estimated $3K.
  • Benjamin F. Edwards & Company first reported a position in Harmony Biosciences in Q4 2023 and held it in 1 quarter.
  • Benjamin F. Edwards & Company's Harmony Biosciences position peaked at $3K in Q4 2023.
  • 208 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q1 2024, filed 29 Apr 2024.